70 related articles for article (PubMed ID: 27133759)
1. A phase II study of nintedanib in patients with relapsed small cell lung cancer.
Han JY; Kim HY; Lim KY; Hwangbo B; Lee JS
Lung Cancer; 2016 Jun; 96():108-12. PubMed ID: 27133759
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).
Ramalingam SS; Belani CP; Mack PC; Vokes EE; Longmate J; Govindan R; Koczywas M; Ivy SP; Gandara DR
J Thorac Oncol; 2010 Aug; 5(8):1279-84. PubMed ID: 20559150
[TBL] [Abstract][Full Text] [Related]
3. A phase II evaluation of nintedanib (BIBF-1120) in the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.
Dizon DS; Sill MW; Schilder JM; McGonigle KF; Rahman Z; Miller DS; Mutch DG; Leslie KK
Gynecol Oncol; 2014 Dec; 135(3):441-5. PubMed ID: 25312396
[TBL] [Abstract][Full Text] [Related]
4. Phase-II trial of rebeccamycin analog, a dual topoisomerase-I and -II inhibitor, in relapsed "sensitive" small cell lung cancer.
Schwandt A; Mekhail T; Halmos B; O'Brien T; Ma PC; Fu P; Ivy P; Dowlati A
J Thorac Oncol; 2012 Apr; 7(4):751-4. PubMed ID: 22425925
[TBL] [Abstract][Full Text] [Related]
5. Nintedanib in NSCLC: evidence to date and place in therapy.
Bronte G; Passiglia F; Galvano A; Barraco N; Listì A; Castiglia M; Rizzo S; Fiorentino E; Bazan V; Russo A
Ther Adv Med Oncol; 2016 May; 8(3):188-97. PubMed ID: 27239237
[TBL] [Abstract][Full Text] [Related]
6. Vascular Endothelial Growth Factor in Plasma and Pleural Effusion Is a Biomarker for Outcome After Bevacizumab plus Carboplatin-Paclitaxel Treatment for Non-small Cell Lung Cancer with Malignant Pleural Effusion.
Tamiya M; Tamiya A; Yasue T; Nakao K; Omachi N; Shiroyama T; Tani E; Hamaguchi M; Morishita N; Suzuki H; Okamoto N; Okishio K; Kawaguchi T; Atagi S; Hirashima T
Anticancer Res; 2016 Jun; 36(6):2939-44. PubMed ID: 27272808
[TBL] [Abstract][Full Text] [Related]
7. Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
Gettinger S; Rizvi NA; Chow LQ; Borghaei H; Brahmer J; Ready N; Gerber DE; Shepherd FA; Antonia S; Goldman JW; Juergens RA; Laurie SA; Nathan FE; Shen Y; Harbison CT; Hellmann MD
J Clin Oncol; 2016 Sep; 34(25):2980-7. PubMed ID: 27354485
[TBL] [Abstract][Full Text] [Related]
8. Effect of Noninvasive Ventilation Delivered by Helmet vs Face Mask on the Rate of Endotracheal Intubation in Patients With Acute Respiratory Distress Syndrome: A Randomized Clinical Trial.
Patel BK; Wolfe KS; Pohlman AS; Hall JB; Kress JP
JAMA; 2016 Jun; 315(22):2435-41. PubMed ID: 27179847
[TBL] [Abstract][Full Text] [Related]
9. Changing trends in diagnosis, staging, treatment and survival in lung cancer: comparison of three consecutive cohorts in an Australian lung cancer centre.
Denton EJ; Hart D; Wainer Z; Wright G; Russell PA; Conron M
Intern Med J; 2016 Aug; 46(8):946-54. PubMed ID: 27177600
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.
Nanda R; Chow LQ; Dees EC; Berger R; Gupta S; Geva R; Pusztai L; Pathiraja K; Aktan G; Cheng JD; Karantza V; Buisseret L
J Clin Oncol; 2016 Jul; 34(21):2460-7. PubMed ID: 27138582
[TBL] [Abstract][Full Text] [Related]
11. Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508).
Belani CP; Dahlberg SE; Rudin CM; Fleisher M; Chen HX; Takebe N; Velasco MR; Tester WJ; Sturtz K; Hann CL; Shanks JC; Monga M; Ramalingam SS; Schiller JH
Cancer; 2016 Aug; 122(15):2371-8. PubMed ID: 27163943
[TBL] [Abstract][Full Text] [Related]
12. Phase I Study of Oral Vinorelbine in Combination with Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Using Two Different Schedules.
Sutiman N; Zhang Z; Tan EH; Ang MK; Tan SW; Toh CK; Ng QS; Chowbay B; Lim WT
PLoS One; 2016; 11(5):e0154316. PubMed ID: 27135612
[TBL] [Abstract][Full Text] [Related]
13. Osimertinib (AZD9291) and CNS Response in Two Radiotherapy-Naïve Patients with EGFR-Mutant and T790M-Positive Advanced Non-Small Cell Lung Cancer.
Ricciuti B; Chiari R; Chiarini P; Crinò L; Maiettini D; Ludovini V; Metro G
Clin Drug Investig; 2016 Aug; 36(8):683-6. PubMed ID: 27177916
[TBL] [Abstract][Full Text] [Related]
14. Crizotinib Resensitization by Compound Mutation.
Bordi P; Del Re M; Tiseo M
N Engl J Med; 2016 May; 374(18):1790. PubMed ID: 27144863
[No Abstract] [Full Text] [Related]
15. Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem.
Lo Russo G; Macerelli M; Platania M; Zilembo N; Vitali M; Signorelli D; Proto C; Ganzinelli M; Gallucci R; Agustoni F; Fasola G; de Braud F; Garassino MC
Curr Drug Targets; 2017; 18(3):341-362. PubMed ID: 27138756
[TBL] [Abstract][Full Text] [Related]
16. BEVERLY: Rationale and Design of a Randomized Open-Label Phase III Trial Comparing Bevacizumab Plus Erlotinib Versus Erlotinib Alone as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Gridelli C; Rossi A; Ciardiello F; De Marinis F; Crinò L; Morabito A; Morgillo F; Montanino A; Daniele G; Piccirillo MC; Normanno N; Gallo C; Perrone F
Clin Lung Cancer; 2016 Sep; 17(5):461-465. PubMed ID: 27209164
[TBL] [Abstract][Full Text] [Related]
17. Treatment of limited-stage small cell lung cancer in the elderly, chemotherapy vs. sequential chemoradiotherapy vs. concurrent chemoradiotherapy: that's the question.
Gridelli C; Casaluce F; Sgambato A; Monaco F; Guida C
Transl Lung Cancer Res; 2016 Apr; 5(2):150-4. PubMed ID: 27186510
[TBL] [Abstract][Full Text] [Related]
18. Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: a randomised controlled trial.
Bendixen M; Jørgensen OD; Kronborg C; Andersen C; Licht PB
Lancet Oncol; 2016 Jun; 17(6):836-844. PubMed ID: 27160473
[TBL] [Abstract][Full Text] [Related]
19. Crizotinib Resensitization by Compound Mutation.
Shaw AT; Engelman JA
N Engl J Med; 2016 May; 374(18):1790-1. PubMed ID: 27144862
[No Abstract] [Full Text] [Related]
20. Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.
Lai XX; Xu RA; Yu-Ping L; Yang H
Onco Targets Ther; 2016; 9():2421-8. PubMed ID: 27143937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
